Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated to acquiring and providing strategic resources and expansion capital to innovative healthcare companies that strive to provide much needed healthcare and related products to patients in need. By partnering with exceptional entrepreneurs we aim to help to create market-leading products and companies in the biomedical and healthcare sector. As entrepreneurs and investors with operational and technical expertise we embrace a collaborative approach to capital formation and business development.
Why Q BioMed
Through Q BioMed investors have the opportunity to invest in some of the most innovative bio-medical products that they may never have known about. Technologies are vetted by analysts, industry KOLs and experts. Your investment is in Q BioMed – so you have public company liquidity without being tied up in a private company with an unknown exit strategy and uncertain value inflection milestones (FDA etc).
Q BioMed aims to mitigate risk by having multiple relationships and assets across a broad spectrum of healthcare companies and sectors. Success being shared as multiple assets mature at different times in their development cycle passing on value to the Q BioMed shareholders.
Q has the ability to fund and/or acquire promising BioMedical assets. We use management’s expertise and network of experts to evaluate undervalued assets and to secure an equity interest in promising technologies and products. We help develop them into high value businesses. Q and its investors will benefit from early positioning in largely illiquid and unknown private assets with multiple potential products and their development cycle and valuation growth as they move forward. By structuring the company to keep overhead to a minimum and costs down there is limited burn and significant upside potential as assets progress through their development cycle.
Q BioMed Inc is assessing multiple BioMedical assets in various areas of healthcare and drug development. Our Pipeline is not complete and not yet formalized. We are actively pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates that we believe will provide a robust technology platform from which to build significant value.
Management and Directors
• Denis D Corin - President and Director - Mr. Denis D. Corin is our President and a director. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental is building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also serves as a Management Consultant to the executives and board of TapImmune Inc., a clinical stage immune-oncology company where had previously served as CEO and President. He has been a Director of Q BioMed, Inc. since April 2015. He served as a Director of TapImmune Inc., from July 2009 to May 2012. He continues to serve as a Director of Soloro Gold and NPX Metals Inc. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
• William Rosenstadt - General and Corporate Securities Counsel and Director - William Rosenstadt is the founding and managing partner of Sanders Ortoli Vaughn-Flam Rosenstadt LLP an international law firm located in New York and has been a practicing attorney since 1995. William advises entrepreneurs, public companies, and other corporate entities with respect to the execution of complex commercial, corporate, and international transactions. William often serves as general counsel to his clients advising them with respect to public and private financings (equity and debt), federal securities law compliance and other merger and acquisition related transactions. Mr. Rosenstadt and his firm are authorized to sponsor issuers on the OTC Markets as Principal American Liaisons (“PAL”) and Designated Advisors for Disclosure (“DAD”) and were instrumental in introducing the Canadian Securities Exchange to the OTC Markets and having it designated as an authorized exchange. Early in his legal career, Mr. Rosenstadt was general counsel to American Industrial Acquisition Corporation, a private equity firm focused on investing in privately held, middle market manufacturers in the wire/cable and defense industries. Mr. Rosenstadt graduated from Syracuse University with a B.A. in 1990 and received his J.D. from the Benjamin N. Cardozo School of Law in 1995. Further, he is admitted to the bars of New York, New Jersey, and Connecticut as well as the Second Circuit of the federal courts of the United States.
• Ari Jatwes - Corporate Advisor and Senior Analyst - Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his tremendous experience in mergers and acquisitions. Over the last decade Ari’s interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. Ari has played an integral role in several successful contracts and transactions in the healthcare space - with emphasis on the life sciences and immunotherapy. Mr. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal.
• David Laskow-Pooley - VP Scientific & Product Development - Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics.
Shares Issued: 9,250,000
Management/Insider Ownership: 3,2 M (35%)
Authorized: 250,000,000 Common, 100,000,000 Preferred
Q Biomed Inc.
A Biotechnology Acceleration Company
501 Madison Ave, 14th Floor
New York, NY 10022
Phone: +1 (888) 357-2435
Email: [email protected]